Amarillo Biosciences, Inc. (OTC.BB:AMAR )

[mickymoose99]

Amarillo Biosciences Teams With Bio-Stasis International to Launch Dietary Supplement Virapress



tweet
Email
Print
..



Companies:
Amarillo Biosciences Inc.

.




Related Quotes




Symbol

Price

Change




AMAR.OB

0.0650

0.00









Press Release Source: Amarillo Biosciences, Inc. On Tuesday July 19, 2011, 11:14 am EDT

AMARILLO, TX--(Marketwire - 07/19/11) - Amarillo Biosciences, Inc. (ABI) (OTC.BB:AMAR - News) today announced that it has formed an alliance with Bio-Stasis International, Inc., a dietary supplement internet marketer, to launch Bio-Stasis International's Virapress. Bio-Stasis plans to embark on an extensive internet marketing program for Virapress on August 1, 2011, targeting alternative and complimentary medical practitioners.

Virapress is a dietary supplement derived from a bovine protein extract produced by ABI and will be marketed with claims to improve health and enhance immunity. In parallel with Bio-Stasis International's internet marketing campaign, ABI will market its bovine extract to health food stores and internationally under ABI's brand name. ABI has already received serious inquiries about distribution rights from marketers in 9 different countries in the Middle East and Africa and has commenced negotiations on international distribution rights.

"We expect our internet marketing campaign to significantly increase the market for Virapress and, also, its primary ingredient, bovine extract," said Lawrence H. Griffin, president, Bio-Stasis International.

Virapress has not been evaluated by the Food and Drug Administration, and should not take the place of a regular medical evaluation by a licensed health practitioner.

About Bio-Stasis International, Inc.

Bio-Stasis is committed to the promotion of natural products which have been shown to promote health and healing. Each Bio-Stasis product must have scientific evidence to support effectiveness, without side effects. For additional information, please visit the Bio-Stasis International Inc.'s website About Virapress

About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 6% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at Amarillo Biosciences.

[smartinvest22]

AMAR went another 7.69% up this AM! The float is pretty tight, looking for some action on here by EOD!